A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies.
genomics
health technology assessment
metabolomics
omics sciences
omics technologies
personalized medicine
proteomics
transcriptomics
value assessment frameworks
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
30 10 2020
30 10 2020
Historique:
received:
01
10
2020
revised:
20
10
2020
accepted:
22
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Omics technologies, enabling the measurements of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools for personalized decision-making. We aimed to identify the existing value assessment frameworks used by health technology assessment (HTA) doers for the evaluation of omics technologies through a systematic review. PubMed, Scopus, Embase and Web of Science databases were searched to retrieve potential eligible articles published until 31 May 2020 in English. Additionally, through a desk research in HTA agencies' repositories, we retrieved the published reports on the practical use of these frameworks. Twenty-three articles were included in the systematic review. Twenty-two frameworks, which addressed genetic and/or genomic technologies, were described. Most of them derived from the ACCE framework and evaluated the domains of analytical validity, clinical validity and clinical utility. We retrieved forty-five reports, which mainly addressed the commercial transcriptomic prognostics and next generation sequencing, and evaluated clinical effectiveness, economic aspects, and description and technical characteristics. A value assessment framework for the HTA evaluation of omics technologies is not standardized and accepted, yet. Our work reports that the most evaluated domains are analytical validity, clinical validity and clinical utility and economic aspects.
Sections du résumé
BACKGROUND
Omics technologies, enabling the measurements of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools for personalized decision-making. We aimed to identify the existing value assessment frameworks used by health technology assessment (HTA) doers for the evaluation of omics technologies through a systematic review.
METHODS
PubMed, Scopus, Embase and Web of Science databases were searched to retrieve potential eligible articles published until 31 May 2020 in English. Additionally, through a desk research in HTA agencies' repositories, we retrieved the published reports on the practical use of these frameworks.
RESULTS
Twenty-three articles were included in the systematic review. Twenty-two frameworks, which addressed genetic and/or genomic technologies, were described. Most of them derived from the ACCE framework and evaluated the domains of analytical validity, clinical validity and clinical utility. We retrieved forty-five reports, which mainly addressed the commercial transcriptomic prognostics and next generation sequencing, and evaluated clinical effectiveness, economic aspects, and description and technical characteristics.
CONCLUSIONS
A value assessment framework for the HTA evaluation of omics technologies is not standardized and accepted, yet. Our work reports that the most evaluated domains are analytical validity, clinical validity and clinical utility and economic aspects.
Identifiants
pubmed: 33143182
pii: ijerph17218001
doi: 10.3390/ijerph17218001
pmc: PMC7663163
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Technol Assess Health Care. 2005 Winter;21(1):89-95
pubmed: 15736519
Eur J Hum Genet. 2007 Sep;15(9):917-21
pubmed: 17534375
Evid Rep Technol Assess (Full Rep). 2007 Dec;(160):1-105
pubmed: 18457476
Am J Prev Med. 2001 Apr;20(3 Suppl):21-35
pubmed: 11306229
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Brief Bioinform. 2018 Mar 1;19(2):286-302
pubmed: 27881428
Genet Test Mol Biomarkers. 2012 Jun;16(6):605-14
pubmed: 22300513
BMC Med Inform Decis Mak. 2012 Oct 19;12:117
pubmed: 23078403
Adv Health Econ Health Serv Res. 2008;19:191-206
pubmed: 19548519
Clin Chem Lab Med. 2010 Oct;48(10):1397-407
pubmed: 20658948
Per Med. 2011 Mar;8(2):191-205
pubmed: 29783413
Int J Technol Assess Health Care. 2011 Oct;27(4):305-12
pubmed: 22004770
Health Technol Assess. 2013 Oct;17(44):1-302
pubmed: 24088296
PLoS One. 2019 Aug 5;14(8):e0219755
pubmed: 31381569
Genet Med. 2005 Sep;7(7):495-500
pubmed: 16170241
Int J Technol Assess Health Care. 2020 Jun;36(3):187-190
pubmed: 32398176
Int J Technol Assess Health Care. 2009 Dec;25 Suppl 2:9-20
pubmed: 20030886
Int J Technol Assess Health Care. 2018 Jan;34(4):368-377
pubmed: 30136642
Med J Islam Repub Iran. 2016 May 03;30:362
pubmed: 27493906
Med Decis Making. 1991 Apr-Jun;11(2):88-94
pubmed: 1907710
Metabolites. 2019 Jun 06;9(6):
pubmed: 31174372
Ont Health Technol Assess Ser. 2017 Apr 11;17(4):1-39
pubmed: 28515818
Int J Technol Assess Health Care. 2003 Spring;19(2):301-16
pubmed: 12862188
Ont Health Technol Assess Ser. 2020 Mar 06;20(11):1-178
pubmed: 32194879
Clin Transl Med. 2014 Mar 29;3(1):7
pubmed: 24679154
Genet Med. 2013 Feb;15(2):115-22
pubmed: 23037935
Genet Med. 2009 Jan;11(1):35-41
pubmed: 19125126
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Ont Health Technol Assess Ser. 2020 Mar 06;20(10):1-234
pubmed: 32284770
Genet Med. 2010 Nov;12(11):686-93
pubmed: 20808229
Health Technol Assess. 2017 Sep;21(51):1-238
pubmed: 28895526
Health Technol Assess. 2019 Mar;23(13):1-226
pubmed: 30917097
Genet Med. 2010 Mar;12(3):153-9
pubmed: 20154628
J Mol Diagn. 2019 Jan;21(1):3-12
pubmed: 30453057
Community Genet. 2006;9(1):27-33
pubmed: 16490956
Genet Med. 2009 Jan;11(1):15-20
pubmed: 19125128
Genet Med. 2009 Jan;11(1):3-14
pubmed: 18813139
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Hum Mol Genet. 2018 May 1;27(R1):R2-R7
pubmed: 29474574
Genet Med. 2013 Jan;15(1):14-24
pubmed: 22955111
Per Med. 2017 May;14(3):235-247
pubmed: 29767583
JAMA. 1988 Sep 23-30;260(12):1743-8
pubmed: 3045356
Genet Med. 2007 Jul;9(7):473-8
pubmed: 17666894